# entry[].resource.text.div
International Patient Summary for PETER KEITH JONES

# entry[].resource.section[].code.coding[].display
Allergies and adverse reactions Document

# entry[].resource.section[].text.div
Code | Type | Recorded On | Asserted By | Clinical Status | Verification Status
No known allergies | Allergy | | Patient/NNJ9186 | active | confirmed

# entry[].resource.section[].text.div
Condition | Category | Recorded On | Clinical Status | Verification Status
Gout | Problem List Item | 2020-10-01 | active | confirmed
Essential hypertension | Problem List Item | 2016-05-25 | active | confirmed

# entry[].resource.section[].text.div
Drug | Status | Effective | Instructions
cilazapril 500 microgram tablet, 90 | Active | 2023-02-23 | Take 1 daily

# entry[].resource.section[].text.div
Vaccine | Status | Occurance | Route | Dose # | Series
Influenza, seasonal, injectable | Completed | 2023-04-12 | Injection, intramuscular | 1 | 1 (Over 65 years (Influenza))
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose | Completed | 2022-08-01 | Injection, intramuscular | 4 | 12 (At risk, no previous history)
zoster vaccine, live | Completed | 2022-07-13 | Injection, intramuscular | 1 | 65Y (65 years)
Influenza, seasonal, injectable | Completed | 2022-06-01 | Injection, intramuscular | 1 | 1 (Over 65 years (Influenza))
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose | Completed | 2022-01-13 | Injection, intramuscular | 3 | 12 (At risk, no previous history)
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose | Completed | 2021-08-27 | Injection, intramuscular | 2 | 12 (At risk, no previous history)
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose | Completed | 2021-08-05 | Injection, intramuscular | 1 | 12 (At risk, no previous history)

# entry[].resource.section[].text.div
Result Group: | GENERAL CHEM.... | Result Date: | 01 Mar 2023 15:06 | Result Status: | completed

Result Name | Value | Reference Range | Abnormal Indicator | Comments
Uric Acid | 0.36 mmol/L | 0.23-0.42

Result Group: | LIPIDS.......... | Result Date: | 23 Feb 2023 14:35 | Result Status: | completed

Result Name | Value | Reference Range | Abnormal Indicator | Comments
Total/HDL Chol Ratio | 2.2 NoUnit | NA
Triglyceride | 1.5 mmol/L | NA
Lipid Comments. | A combined CVD risk of which lipids is one component should be estimated to guide CVD risk management decisions. If lipid modifying medication is considered suggest checking first for treatable secondary causes of dyslipidaemia. | NA
HDL Cholesterol | 1.38 mmol/L | NA
LDL Chol - calculated | 1.0 mmol/L | NA
Cholesterol | 3.0 mmol/L | NA

Result Group: | Iron Studies | Result Date: | 20 Oct 2022 13:05 | Result Status: | completed

Result Name | Value | Reference Range | Abnormal Indicator | Comments
Ferritin | 280 ug/L | 20-450

Result Group: | GENERAL CHEM.... | Result Date: | 20 Oct 2022 13:05 | Result Status: | completed

Result Name | Value | Reference Range | Abnormal Indicator | Comments
Sodium | 141 mmol/L | 135-145
Creatinine | 79 umol/L | 60-105
Uric Acid | 0.43 mmol/L | 0.23-0.42 | H | The urate target level for gout management is <0.36 mmol/L
eGFR | 89 mL/min | >60
Potassium | 3.9 mmol/L | 3.5-5.2

Result Group: | CALCIUM......... | Result Date: | 20 Oct 2022 13:05 | Result Status: | completed

Result Name | Value | Reference Range | Abnormal Indicator | Comments
Calcium (adjusted for Albumin) | 2.25 mmol/L | 2.10-2.55
Phosphorus | 1.00 mmol/L | 0.70-1.50
Calcium | 2.26 mmol/L | 2.10-2.55

Result Group: | B12 and folate | Result Date: | 20 Oct 2022 13:05 | Result Status: | completed

Result Name | Value | Reference Range | Abnormal Indicator | Comments
Folate | 10.2 nmol/L | 7.0-45.0
Vitamin B12 | 208 pmol/L | 110-650

Result Group: | TFTs............ | Result Date: | 20 Oct 2022 13:05 | Result Status: | completed

Result Name | Value | Reference Range | Abnormal Indicator | Comments
TSH | 1.80 mU/L | 0.3-5.0

Result Group: | Liver Function Tests | Result Date: | 20 Oct 2022 13:05 | Result Status: | completed

Result Name | Value | Reference Range | Abnormal Indicator | Comments
GGT | 18 U/L | 0-60
ALT | 16 U/L | 0-55
Globulin | 30 g/L | 25-35
Alk Phosphatase | 63 U/L | 40-130
Bilirubin total | 9 umol/L | 0-20
Albumin | 38 g/L | 34-48
Total Protein | 68 g/L | 60-80

Result Group: | LIPIDS.......... | Result Date: | 20 Oct 2022 13:05 | Result Status: | completed

Result Name | Value | Reference Range | Abnormal Indicator | Comments
HDL Cholesterol | 1.19 mmol/L | NA
Total/HDL Chol Ratio | 5.0 NoUnit | NA
LDL Chol - calculated | 4.1 mmol/L | NA
Cholesterol | 5.9 mmol/L | NA
Lipid Comments. | A combined CVD risk of which lipids is one component should be estimated to guide CVD risk management decisions. If lipid modifying medication is considered suggest checking first for treatable secondary causes of dyslipidaemia. | NA
Triglyceride | 1.5 mmol/L | NA

Result Group: | HBA1c | Result Date: | 20 Oct 2022 12:35 | Result Status: | completed

Result Name | Value | Reference Range | Abnormal Indicator | Comments
HbA1c (IFCC) | 32 mmol/mol | 0-40 | (<41) If used as a screening test, diabetes is virtually

Result Group: | CBC | Result Date: | 20 Oct 2022 12:05 | Result Status: | completed

Result Name | Value | Reference Range | Abnormal Indicator | Comments
MCH | 31 pg | 27-33
HAEMOGLOBIN | 146 g/L | 130-175
Differential: Monocyte | 0.3 x10E9/L | 0.2-1.0
Differential: Lymphocyte | 1.5 x10E9/L | 1.0-4.0
Differential: Basophil | 0.1 x10E9/L | 0-0.2
Differential: Eosinophil | 0.2 x10E9/L | 0.0-0.5
PLATELET COUNT | 209 x10E9/L | 150-400
WBC | 4.8 x10E9/L | 4.0-11.0
HCT | 0.43 L/L | 0.40-0.52
Differential: Neut Seg | 2.7 x10E9/L | 1.9-7.5
MCV | 92 fL | 80-99

# entry[].resource.text.div
Name: PETER KEITH JONES

# entry[].resource.text.div
Name: NorthCare Pukete Road-Thomas Road

# entry[].resource.text.div
Role: Doctor

# entry[].resource.text.div
Name: Hashira COORAY

# entry[].resource.text.div
Name: NorthCare Pukete Road-Thomas Road

# entry[].resource.text.div
No known allergies ()

# entry[].resource.text.div
Gout (disorder)

# entry[].resource.text.div
Essential hypertension

# entry[].resource.text.div
31099751000116106 (cilazapril 500 microgram tablet, 90)

# entry[].resource.text.div
99006 (Influenza)

# entry[].resource.text.div
208 (Pfizer/BioNtech)

# entry[].resource.vaccineCode.coding[].display
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose

# entry[].resource.text.div
121 (Zoster)

# entry[].resource.text.div
99006 (Influenza)

# entry[].resource.text.div
208 (Pfizer/BioNtech)

# entry[].resource.vaccineCode.coding[].display
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose

# entry[].resource.text.div
208 (Pfizer/BioNtech)

# entry[].resource.vaccineCode.coding[].display
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose

# entry[].resource.text.div
208 (Pfizer/BioNtech)

# entry[].resource.vaccineCode.coding[].display
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose

# entry[].resource.text.div
0170 (Iron Studies)

# entry[].resource.text.div
0055 (GENERAL CHEM....)

# entry[].resource.text.div
0055 (GENERAL CHEM....)

# entry[].resource.text.div
0320 (CALCIUM.........)

# entry[].resource.text.div
4014 (CBC)

# entry[].resource.text.div
0063 (HBA1c)

# entry[].resource.text.div
1960 (B12 and folate)

# entry[].resource.text.div
1540 (TFTs............)

# entry[].resource.text.div
1080 (LIPIDS..........)

# entry[].resource.text.div
0100 (Liver Function Tests)

# entry[].resource.text.div
1080 (LIPIDS..........)

# entry[].resource.text.div
Ferritin

# entry[].resource.code.coding[].display
Ferritin [Mass/volume] in Serum or Plasma

# entry[].resource.text.div
Sodium

# entry[].resource.code.coding[].display
Sodium [Moles/volume] in Serum or Plasma

# entry[].resource.text.div
Creatinine

# entry[].resource.code.coding[].display
Creatinine [Moles/volume] in Serum or Plasma

# entry[].resource.text.div
Uric Acid

# entry[].resource.note[].text
The urate target level for gout management is <0.36 mmol/L

# entry[].resource.text.div
eGFR

# entry[].resource.code.coding[].display
Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

# entry[].resource.text.div
Potassium

# entry[].resource.code.coding[].display
Potassium [Moles/volume] in Serum or Plasma

# entry[].resource.text.div
Uric Acid

# entry[].resource.text.div
Calcium (adjusted for Albumin)

# entry[].resource.code.coding[].display
Calcium [Moles/volume] corrected for albumin in Serum or Plasma

# entry[].resource.text.div
Phosphorus

# entry[].resource.code.coding[].display
Phosphate [Moles/volume] in Serum or Plasma

# entry[].resource.text.div
Calcium

# entry[].resource.code.coding[].display
Calcium [Moles/volume] in Serum or Plasma

# entry[].resource.text.div
MCH

# entry[].resource.text.div
HAEMOGLOBIN

# entry[].resource.text.div
Differential: Monocyte

# entry[].resource.text.div
Differential: Lymphocyte

# entry[].resource.text.div
Differential: Basophil

# entry[].resource.text.div
Differential: Eosinophil

# entry[].resource.text.div
PLATELET COUNT

# entry[].resource.code.coding[].display
Platelets [#/volume] in Blood by Automated count

# entry[].resource.text.div
WBC

# entry[].resource.code.coding[].display
Leukocytes [#/volume] in Blood by Automated count

# entry[].resource.text.div
HCT

# entry[].resource.text.div
Differential: Neut Seg

# entry[].resource.text.div
MCV

# entry[].resource.text.div
HbA1c (IFCC)

# entry[].resource.code.coding[].display
Hemoglobin A1c/Hemoglobin.total in Blood by IFCC protocol

# entry[].resource.note[].text
(<41)  If used as a screening test, diabetes is virtually

# entry[].resource.text.div
Folate

# entry[].resource.code.coding[].display
Folate [Moles/volume] in Serum or Plasma

# entry[].resource.text.div
Vitamin B12

# entry[].resource.code.coding[].display
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma

# entry[].resource.text.div
TSH

# entry[].resource.code.coding[].display
Thyrotropin [Units/volume] in Serum or Plasma

# entry[].resource.text.div
Total/HDL Chol Ratio

# entry[].resource.code.coding[].display
Cholesterol.total/Cholesterol in HDL [Molar ratio] in Serum or Plasma

# entry[].resource.text.div
Triglyceride

# entry[].resource.code.coding[].display
Triglyceride [Moles/volume] in Serum or Plasma

# entry[].resource.text.div
Lipid Comments.

# entry[].resource.valueString
A combined CVD risk of which lipids is one component should be estimated to guide CVD risk management decisions. If lipid modifying medication is considered suggest checking first for treatable secondary causes of dyslipidaemia.

# entry[].resource.text.div
HDL Cholesterol

# entry[].resource.code.coding[].display
Cholesterol in HDL [Moles/volume] in Serum or Plasma

# entry[].resource.text.div
LDL Chol - calculated

# entry[].resource.code.coding[].display
Cholesterol in LDL [Moles/volume] in Serum or Plasma by calculation

# entry[].resource.text.div
Cholesterol

# entry[].resource.code.coding[].display
Cholesterol [Moles/volume] in Serum or Plasma

# entry[].resource.text.div
GGT

# entry[].resource.code.coding[].display
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma

# entry[].resource.text.div
ALT

# entry[].resource.code.coding[].display
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma

# entry[].resource.text.div
Globulin

# entry[].resource.code.coding[].display
Globulin [Mass/volume] in Serum by calculation

# entry[].resource.text.div
Alk Phosphatase

# entry[].resource.code.coding[].display
Deprecated Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma

# entry[].resource.text.div
Bilirubin total

# entry[].resource.code.coding[].display
Bilirubin.total [Moles/volume] in Serum or Plasma

# entry[].resource.text.div
Albumin

# entry[].resource.code.coding[].display
Albumin [Mass/volume] in Serum or Plasma

# entry[].resource.text.div
Total Protein

# entry[].resource.code.coding[].display
Protein [Mass/volume] in Serum or Plasma

# entry[].resource.text.div
HDL Cholesterol

# entry[].resource.code.coding[].display
Cholesterol in HDL [Moles/volume] in Serum or Plasma

# entry[].resource.text.div
Total/HDL Chol Ratio

# entry[].resource.code.coding[].display
Cholesterol.total/Cholesterol in HDL [Molar ratio] in Serum or Plasma

# entry[].resource.text.div
LDL Chol - calculated

# entry[].resource.code.coding[].display
Cholesterol in LDL [Moles/volume] in Serum or Plasma by calculation

# entry[].resource.text.div
Cholesterol

# entry[].resource.code.coding[].display
Cholesterol [Moles/volume] in Serum or Plasma

# entry[].resource.text.div
Lipid Comments.

# entry[].resource.valueString
A combined CVD risk of which lipids is one component should be estimated to guide CVD risk management decisions. If lipid modifying medication is considered suggest checking first for treatable secondary causes of dyslipidaemia.

# entry[].resource.text.div
Triglyceride

# entry[].resource.code.coding[].display
Triglyceride [Moles/volume] in Serum or Plasma

# entry[].resource.text.div
Role: Clinical pathologist